Celprogen introduces in vivo model for human glioblastoma

A study published in the British medical journal Lancet yesterday suggesting that testing all adults in Africa annually for HIV and immediately treating every person who tests positive could halt the AIDS epidemic in Africa within a decade has spurred the AIDS Healthcare Foundation (AHF) to renew its call for the massive scale up of,

Full Post: AHF: Lancet’s Africa AIDS study shows global testing woefully under-funded

Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma.

This in vivo model system has been validated within United States research facilities for testing novel drug candidates against Human Glioblastoma.

Celprogen’s in vivo model system would enable scientists all over the world to test their potential drug candidates against Human Brain Cancer (GBM), which is one of the hardest human cancers to treat and diagnose.

Celprogen has established a Drug Discovery program to provide drug efficacy testing services to major Pharmaceutical firms for their potential drugs against Human Glioblastoma. The other in vivo cancer model systems in the pipe line at Celprogen are: breast cancer, prostate cancer, liver cancer, colon cancer, lung cancer and pancreatic cancer that are scheduled to be released as early as the beginning of second quarter 2009. These in vivo cancer model systems are being generated from already established Celprogen’s Cancer Stem Cells.



Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead. But Dr Stephen Poole, speaking at the British Pharmacological Society’s Winter Meeting in Brighton, said that research is still “ongoing” to understand why the

Full Post: Lessons from Northwick Park drug-trial disaster

Delcath Systems, Inc. has announced that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The eleven participating cancer centers in this trial continue to evaluate and enroll patients and the Company looks forward to completing enrollment

Full Post: Delcath Systems enrols first fifty percent in trial treating metastatic cutaneous and ocular melanoma to the liver

Aduromed Industries, Inc. has announced that it successfully filed a U.S. patent on November 24, 2008 to protect the Company’s proprietary technology for its new standard, containerized MedClean Systems that provide a turnkey solution for onsite regulated medical waste sterilization and volume reduction. The patent application, entitled “Containerized Medical Waste Treatment System and Related Method,”

Full Post: Aduromed Industries files patent application for containerized medical waste treatment system

Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma-the most common and deadly brain cancer in humans-that closely resembles the development and progression of human brain tumors that arise naturally. “Mouse models of human cancer have taught us a great deal about the basic principles of cancer biology,”

Full Post: A novel glioblastoma mouse model developed

Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer. But can this common anti-depressant help to fight cancer itself? Dr. Dan Peer of the Department of Cell Research and Immunology at Tel Aviv University is proving that it can. A study he and his colleagues recently completed

Full Post: Prozac enhances effectiveness of anti-cancer drug